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hemodynamic instability following carotid
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Brant W. Ullery, MD, Derek P. Nathan, MD, Eric K. Shang, MD, Grace J. Wang, MD,
Benjamin M. Jackson, MD, Erin H. Murphy, MD, Ronald M. Fairman, MD, and
Edward Y. Woo, MD, Philadelphia, Pa
Objective: To explore the incidence, predictors, and outcomes of hemodynamic instability (HI) following carotid
angioplasty and stenting (CAS).
Methods: We retrospectively evaluated data on 257 CAS procedures performed in 245 patients from 2002 to 2011 at
a single institution. The presence of periprocedural HI, as deﬁned by hypertension (systolic blood pressure >160 mm
Hg), hypotension (systolic blood pressure <90 mm Hg), and/or bradycardia (heart rate <60 beats per minute), was
recorded. Clinically signiﬁcant HI (CS-HI) was deﬁned as periprocedural HI lasting greater than 1 hour in total dura-
tion. Logistic regression was used to analyze the role of multiple demographic, clinical, and procedural variables.
Results: Mean age was 70.9 6 9.9 years (67% male). HI occurred following 84% (n[ 216) of procedures. The incidence
of hypertension, hypotension, and bradycardia was 54%, 31%, and 60%, respectively. Sixty-three percent of cases involved
CS-HI. Recent stroke was an independent risk factor for the development of CS-HI (odds ratio, 5.24; conﬁdence interval,
1.28-21.51; P[ .02), whereas baseline chronic obstructive pulmonary disease was protective against CS-HI (odds ratio,
0.34; conﬁdence interval, 0.15-0.80; P[ .01). Patients with CS-HI were more likely to experience periprocedural stroke
compared to other patients (8% vs 1%; P [ .03). There were no signiﬁcant differences in the incidence of mortality or
other major complications between those with and without CS-HI.
Conclusions: HI represents a common occurrence following CAS. While the presence of periprocedural HI alone did not
portend a worse clinical outcome, CS-HI was associated with increased risk of stroke. Expeditious intervention to prevent
and manage CS-HI is of critical importance in order to minimize adverse clinical events following CAS. (J Vasc Surg
2013;58:917-25.)Carotid angioplasty and stenting (CAS) represents an
alternative to conventional carotid endarterectomy (CEA)
in certain patient populations.1 Hemodynamic instability
(HI) has long been associated with CEA and has been
linked to adverse clinical events.2,3 Similarly, catheter-
related instrumentation of adventitial baroreceptors at the
level of the carotid sinus, along with balloon angioplasty
and stent deployment, may trigger a baroreceptor reﬂex
and result in a variety of hemodynamic derangements
following CAS procedures.
There are conﬂicting reports in the literature regarding
the true incidence and relative clinical impact of periproce-
dural HI in patients undergoing CAS procedures. Hemo-
dynamic depression, including the presence of bradycardiathe Division of Vascular Surgery and Endovascular Therapy, Depart-
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://dx.doi.org/10.1016/j.jvs.2012.10.141or hypotension, has been cited to occur in 5% to 76% of
CAS procedures.4-9 Extreme or prolonged (>1 hour)
episodes of periprocedural HI after CAS have been shown
in some studies to be associated with worse clinical
outcomes.4,10,11
We aimed to examine our clinical experience with CAS
over the last decade in order to determine the incidence,
predictors, and outcomes of patients with HI following
CAS.
METHODS
Patient selection. A retrospective review of a prospec-
tively maintained clinical database was conducted for all
patients undergoing CAS procedures between 2002 and
2011 at a single academic medical center. Preoperative
imaging, consisting of carotid duplex ultrasound, magnetic
resonance angiography, and/or computed tomographic
angiography, was obtained for all patients in order to docu-
ment the degree of carotid stenosis. Indications for CAS
included symptomatic carotid stenosis of $70% or asymp-
tomatic carotid stenosis of $80%, as well as one or more of
the following high-risk anatomic factors: high carotid
artery bifurcation (above the level of the second cervical
vertebrae), previous CEA, presence of tracheostomy, prior
neck radiation, or prior neck dissection. In addition,
patients with high-grade carotid stenosis and signiﬁcant
medical comorbidities were considered for CAS, including917
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Heart Association class III or IV congestive heart failure, or
steroid-dependent chronic obstructive pulmonary disease
(COPD).
Carotid angioplasty and stenting protocol. All
procedures were performed percutaneously via puncture
of the femoral artery with local anesthesia using 1% xylo-
caine. Weight-adjusted heparin (70 U/kg) was adminis-
tered prior to wire or catheter manipulation in the aortic
arch. Selective angiography of the stenotic carotid artery
was performed in at least two projections. Procedures were
performed via a long 6- or 7F sheath. All interventions
were performed over a 0.014-inch system. Uncovered self-
expanding stents were used exclusively (Accunet; Guidant/
Abbott, Abbott Park, Ill or Wallstent; Boston Scientiﬁc,
Natick, Mass). Stent diameter and length were selected
according to the anatomy and lesion being treated. Distal
embolic protection devices were used whenever possible.
Balloon predilation was performed infrequently. Post-
stenting angioplasty was routinely performed using a 5- or
6-mm-diameter angioplasty balloon based on completion
angiogram.
Intravenous atropine was administered in cases
involving CAS-induced bradycardia or asystole. Prophy-
lactic atropine or glycopyrrolate was used selectively based
on individual surgeon preference. Patients were preferen-
tially started on aspirin and clopidogrel preoperatively
and continued on that regimen for at least 1 month
postoperatively.
Perioperative hemodynamic monitoring. CAS
procedures were performed in an endovascular-equipped
hybrid operating room using local anesthesia and
conscious sedation that was monitored by an anesthesiol-
ogist. Baseline heart rate (HR), systolic blood pressure
(SBP), and mean arterial pressure were recorded prior to
the administration of anesthesia. Intraprocedural hemody-
namics were monitored by the anesthesia staff and auto-
matically transmitted into the electronic procedural record.
Noninvasive blood pressure measurements were obtained
during the procedure at a minimum of 5-minute intervals
and more frequently during the actual carotid manipula-
tion. Following the CAS procedure, patients were trans-
ferred to the postanesthesia care unit, and vital signs were
obtained every 15 minutes. Patients were then transferred
to the intermediate care unit where neurovascular checks
and vital signs were obtained on an hourly basis.
The presence and duration of periprocedural HI,
deﬁned as hypertension (SBP >160 mm Hg), hypotension
(SBP <90 mm Hg), and/or bradycardia (heart rate <60
beats per minute [bpm]), was recorded for all patients.
Clinically signiﬁcant HI (CS-HI) was deﬁned as periproce-
dural HI lasting greater than 1 hour in total duration.
Periprocedural hypotension was treated with intrave-
nous ﬂuids as tolerated by the cardiopulmonary status of
the individual patient. Persistent hypotension refractory
to volume resuscitation was treated with phenylephrine at
a dose of 50 mcg/min and titrated to a maximum of
300 mcg/min. Persistent hypertension was treated withnicardipine at a dose of 5 mg/hr and titrated up to
a maximum dose of 15 mg/hr. The titration of vasoactive
agents was guided by a target mean arterial blood pressure
of 75 to 85 mm Hg. Symptomatic or extreme (<40 bpm)
periprocedural bradycardia was treated with atropine and, if
persistent, prompted cardiology consultation.
Outcome measures. Baseline demographics, cardio-
vascular risk factors, history of prior stroke, previous carotid
intervention (CAS or CEA), severity of carotid stenosis
on angiography, laterality of carotid stenosis, acuity,
procedure-related variables, and perioprocedural out-
comes were assessed. Logistic regression was used to
identify risk factors for the development of periprocedural
HI and CS-HI. Outcome variables included death, MI,
stroke, renal failure, respiratory failure, and access site
complications. MI was deﬁned on the basis of cardiac
enzyme elevation in combination with electrocardiogram
tracing consistent with new ischemia and/or evidence of
new regional wall motion abnormality on echocardiog-
raphy. Stroke was deﬁned as any new focal or global
neurologic deﬁcit lasting greater than 24 hours with asso-
ciated radiographic evidence of acute intracranial abnor-
mality. All patients demonstrating clinical evidence of
a periprocedural neurologic deﬁcit were promptly evalu-
ated by a stroke neurologist.
Statistical analysis. Clinical data were recorded and
tabulated with Microsoft Excel (Microsoft Corp, Red-
mond, Wash). Continuous variables were compared using
the unpaired Student t-test. c2 or Fisher exact test was
employed to examine group differences in cases involving
dichotomous variables. Multivariate logistic regression
was performed in order to identify risk factors for the devel-
opment of HI and to assess the impact of periprocedural
HI on adverse clinical events.
Results are presented as mean 6 standard deviation for
continuous variables and frequencies for categorical vari-
ables. Odds ratios (ORs) are presented with 95% conﬁdence
intervals (CIs). Statistical signiﬁcance was set at P values less
than .05 for all analyses. Statistical analyses were performed
using Matlab software (The Mathworks, Natick, Mass).
RESULTS
HI. A total of 257 CAS procedures were performed in
245 patients during the study period. Mean age was
70.9 6 9.9 years (66.9% male). HI occurred following
84% (n ¼ 216) of procedures. The incidence of hyperten-
sion, hypotension, and bradycardia was 54% (n ¼ 138),
31% (n ¼ 79), and 60% (n ¼ 155), respectively. Concom-
itant periprocedural hypotension and bradycardia occurred
in 9% (n ¼ 23) of patients. Of the 155 patients experi-
encing bradycardia, 59 of them (38%) developed brady-
cardia at some point during the CAS procedure, which
generally persisted beyond the procedure. No cases
required temporary or permanent pacing. Intraprocedural
hypotension occurred in only a minority of patients, with
82% of hypotensive episodes (n ¼ 65) developing in the
postprocedural setting. Sixty-one percent of hypertensive
episodes (n ¼ 84) occurred during the CAS procedure.
Table I. Hemodynamic data of patients with and without HI following CAS
Without HI, mean 6 SD
(n ¼ 41)
With HI, mean 6 SD
(n ¼ 216) P
Preprocedure
SBP (mm Hg) 145 6 5 155 6 14 .02
MAP (mm Hg) 93 6 5 95 6 17 .28
HR (beats/min) 82 6 6 73 6 6 <.001
Intraprocedure
SBP (mm Hg), max 150 6 15 164 6 24 <.001
SBP (mm Hg), min 112 6 10 115 6 19 .45
MAP (mm Hg), max 95 6 12 99 6 15 .13
MAP (mm Hg), min 73 6 9 71 6 15 .52
HR (beats/min), max 92 6 14 85 6 14 .007
HR (beats/min), min 76 6 13 62 6 11 <.001
Postprocedure
0-3 hours
SBP (mm Hg), max 145 6 4 156 6 7 .006
SBP (mm Hg), min 106 6 8 107 6 22 .82
MAP (mm Hg), max 92 6 3 95 6 1 .16
MAP (mm Hg), min 76 6 3 73 6 16 .21
HR (beats/min), max 87 6 4 80 6 5 .001
HR (beats/min), min 72 6 0.4 62 6 1 <.001
3-24 hours
SBP (mm Hg), max 142 6 25 155 6 3 <.001
SBP (mm Hg), min 108 6 2 106 6 26 .57
MAP (mm Hg), max 89 6 9 93 6 14 .16
MAP (mm Hg), min 66 6 2 64 6 11 .24
HR (beats/min), max 88 6 8 79 6 3 <.001
HR (beats/min), min 71 6 9 59 6 3 <.001
24-48 hours
SBP (mm Hg), max 134 6 8 149 6 8 .001
SBP (mm Hg), min 111 6 15 107 6 28 .40
MAP (mm Hg), max 81 6 4 89 6 13 .01
MAP (mm Hg), min 66 6 1 64 6 11 .47
HR (beats/min), max 91 6 16 79 6 1 <.001
HR (beats/min), min 77 6 22 61 6 3 <.001
CAS, Carotid angioplasty and stenting; HI, hemodynamic instability; HR, heart rate; min, minimum; MAP, mean arterial pressure; max, maximum;
SBP, systolic blood pressure; SD, standard deviation.
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78% of cases involving periprocedural bradycardia. Overall,
35% of patients with periprocedural HI required vaso-
pressor therapy, including 50 of 116 patients (43%) with
CS-HI. The mean duration of individual periprocedural
hemodynamic parameters includes the following: hyper-
tension, 3.1 hours; hypotension, 1.5 hours; and brady-
cardia, 10.7 hours. The duration of actual hypotension,
deﬁned as SBP <90 mm Hg, was only 1.5 hours, as the
mean arterial pressure was readily increased to make the
patient normotensive. The mean duration of vasopressor
therapy was 26.9 hours. Periprocedural hemodynamic data
are presented in Table I.
Comorbid status, previous neck intervention (CEA,
CAS, dissection, radiation), intraoperative administration
of atropine or glycopyrrolate, laterality, presence of carotid
symptoms, degree of carotid stenosis, contralateral carotid
occlusion, balloon diameter or length, stent manufacturer,
and stent diameter or length were not predictive of peri-
procedural HI (Tables II and III).
There was no difference in periprocedural morbidity or
mortality observed between those with and without HI(Table IV). Total hospital length of stay was longer for
patients with periprocedural HI (2.22 vs 1.47 days;
P ¼ .03). The single mortality in this series occurred in
a 68-year-old male with a history of symptomatic critical
(>95%) left carotid stenosis who had previously undergone
coronary artery bypass grafting and ipsilateral CEA. While
the CAS procedure was uncomplicated, he did experience
approximately 3 hours of asymptomatic hypotension and
bradycardia early in the postprocedural setting that resolved
with mild volume resuscitation. The patient was discharged
2 days following the procedure but ultimately died 1 week
later due to intracranial hemorrhage. All of the remaining
periprocedural strokes (n¼ 10) were ipsilateral and embolic
in nature. Three patients manifested neurologic deﬁcits
during the procedure; the remaining patients had onset of
stroke within 24 hours following the CAS procedure.
One-half of these patients had full resolution of neurologic
deﬁcits at the time of hospital discharge, whereas the other
ﬁve patients were discharged with only partial neurologic
recovery (mild hemiparesis, n ¼ 4; mild aphasia, n ¼ 1).
A total of 116 (46%) cases involved prophylactic
administration of atropine or glycopyrrolate. Incidence of
Table II. Baseline demographics, comorbidities, and
carotid stenosis disease characteristics of patients with and
without HI following CAS
Without HI,
No. (%) or
mean 6 SD
(n ¼ 41)
With HI,
No. (%) or
mean 6 SD
(n ¼ 216) P
Demographics
Age, years 68.8 6 9.5 71.2 6 3.3 .14
Gender, female 13 (32) 72 (33) >.99
Comorbidities
Hypertension 38 (93) 190 (88) .59
Prior stroke 11 (27) 62 (29) >.99
Atrial ﬁbrillation 3 (7) 25 (12) .59
Prior MI 10 (24) 32 (15) .16
CRIa 9 (22) 45 (21) .84
COPD 8 (20) 28 (13) .32
Hyperlipidemia 30 (73) 144 (67) .22
Tobacco use 21 (51) 123 (57) .50
CAD 26 (63) 118 (55) .31
Diabetes 19 (46) 66 (31) .07
Previous ipsilateral carotid
intervention
CEA 11 (27) 55 (25) .85
CAS 8 (20) 24 (11) .19
Symptoms
None 28 (68) 158 (73) .57
TIA 13 (32) 46 (21) .16
Stroke 0 (0) 12 (6) .22
Cause of stenosis
Atherosclerosis 34 (83) 192 (89) .30
Radiation 5 (12) 31 (14) >.99
Neck dissection 5 (12) 21 (10) .58
Stenosis, %
60-69 0 (0) 4 (19) >.99
70-79 3 (7) 13 (6) .73
80-89 15 (37) 92 (43) .50
>90 23 (56) 107 (50) .50
Contralateral carotid
occlusion
4 (10) 24 (11) >.99
Laterality >.99
Left 20 (49) 108 (50)
Right 21 (51) 108 (50)
CAD, Coronary artery disease; CAS, carotid angioplasty and stenting; CEA,
carotid endarterectomy; COPD, chronic obstructive pulmonary disease;
CRI, chronic renal insufﬁciency; HI, hemodynamic instability; MI,
myocardial infarction; TIA, transient ischemic attack.
aCreatinine $1.5 mg/dL.
Table III. Procedural characteristics of patients with and
without HI following CAS
Without HI,
No. (%) or
mean 6 SD
(n ¼ 41)
With HI,
No. (%) or
mean 6 SD
(n ¼ 216) P
Duration of procedure, minutes 51.0 6 13.4 52.7 6 14.0 .63
Anesthesia .31
General 2 (5) 5 (2)
Local 39 (95) 211 (98)
Maximum stent diameter .30
#8 mm 34 (83) 192 (89)
>8 mm 7 (17) 24 (11)
Maximum stent length .86
#40 mm 18 (45) 90 (42)
>40 mm 23 (55) 126 (58)
Maximum balloon diameter .71
#5 mm 27 (66) 150 (69)
>5 mm 14 (34) 66 (31)
Maximum balloon length .62
#20 mm 4 (10) 29 (13)
>20 mm 37 (90) 187 (87)
CAS, Carotid angioplasty and stenting; HI, hemodynamic instability.
Table IV. Periprocedural outcomes of patients with and
without HI following CAS
Without HI,
No. (%) or
mean 6 SD
(n ¼ 41)
With HI,
No. (%) or
mean 6 SD
(n ¼ 216) P
Complications
Mortality 0 (0) 1 (0) 1.00
Stroke 1 (2) 10 (5) 1.00
MI 0 (0) 1 (0) 1.00
Renal failure 0 (0) 1 (0) 1.00
Hemorrhagic 1 (2) 2 (1) 1.00
Respiratory failure 0 (0) 0 (0) 1.00
Length of stay, days
Intensive care unit 0.08 6 0.05 0.15 6 0.01 .55
Total 1.47 6 0.33 2.22 6 1.41 .03
CAS, Carotid angioplasty and stenting; HI, hemodynamic instability; MI,
myocardial infarction.
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(n ¼ 80), respectively. Among cases involving prophylactic
anticholingeric therapy, the presence of HI or CS-HI was
not associated with a signiﬁcant difference in the incidence
of periprocedural stroke, MI, or death. Moreover, there
was no difference in outcomes in patients with CS-HI inde-
pendent of whether they did or did not receive prophylactic
anticholingerics (stroke, 7.5% vs 8.3%; P ¼ 1.0; MI, 0% vs
2.8%; P ¼ .31; in-hospital mortality, 1.3% vs 0%; P ¼ 1.0).
Of note, a total of 84 patients had an SBP greater than
160mmHg at the start of the CAS procedure. Eighty-seven
percent (n ¼ 73) of these patients continued to meet
our deﬁnition of hypertension in the intraprocedural and/
or postprocedural period. Moreover, 22 patients had anHR <60 bpm documented immediately prior to the start
of the CAS procedure. All 22 of these patients continued
to have HRs <60 bpm during or after the procedure. The
results of our statistical analysis did not signiﬁcantly change
following the elimination of these select patients with pre-
procedural hypertension or bradycardia.
Impact of HI duration. Sixty-three percent (n¼ 116)
of cases involving HI had a total duration of periprocedural
HI exceeding 1 hour. Among these cases of prolonged HI,
45% (n¼ 52) involved hypertension, 16% (n¼ 18) involved
hypotension, and 71% (n ¼ 82) involved bradycardia, with
some patients experiencing derangements in multiple
hemodynamic parameters (eg, bradycardia and hypoten-
sion). This subgroup of prolonged HI, representing 45%
of all procedures in this series, was categorized as CAS
Fig. Study design. CAS, Carotid angioplasty and stenting; HI, hemodynamic instability.
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maining procedures, including both those with HI lasting
less than 1 hour in duration (n ¼ 100) and those without
any periprocedural HI (n ¼ 41), were categorized as all
others (n¼ 141). The Fig illustrates the overall study design
and composition of these subgroups.
Female gender (41% vs 26%; P ¼ .01), baseline hyper-
tension (92% vs 85%; P ¼ .05), and recent stroke (8% vs
2%; P ¼ .04) were associated with the development of CS-
HI in univariate analysis, whereas a history of either
COPD (8% vs 19%; P ¼ .01) or previous CAS procedure
(1% vs 6%, P ¼ .03) appeared to be protective against CS-
HI (Table V). In multivariate analysis, recent stroke
remained an independent predictor of CS-HI (OR, 5.24;
CI, 1.28-21.51; P ¼ .02). Baseline COPD (OR, 0.34; CI,
0.15-0.80; P ¼ .01) continued to be protective against the
development of CS-HI in multivariate analysis (Table VI).
Patients exhibiting evidence of CS-HI were more likely
to experience periprocedural stroke compared with other
patients (8% vs 1%, P¼.03). There were no signiﬁcant dif-
ferences in the incidence of mortality, length of stay, or
other major complications between those with and without
CS-HI following CAS procedures (Table VII). The impact
of speciﬁc hemodynamic derangements on the development
of periprocedural complications is featured in Table VIII.
DISCUSSION
In the present study, we found that over 80% of
patients undergoing CAS developed some form of peripro-
cedural HI. The incidence of hypertension, hypotension,
and bradycardia in our series was 54%, 31%, and 60%,respectively. Reported incidences of HI as well as individual
hemodynamic parameters following CAS procedures vary
widely in the literature, ranging from 7% to 39% for hyper-
tension, 5% to 76% for bradycardia, and 14% to 28% for
hypotension.4,6,7,9,12,13 Such variability with regard to re-
ported incidences of HI is likely a reﬂection, at least in
part, of the inconsistency in hemodynamic deﬁnitions
used in previous clinical studies. The deﬁnition used
in our study for HI, including hypertension (SBP
>160 mm Hg), hypotension (SBP <90 mm Hg), and
bradycardia (HR <60 bpm), was selected to facilitate
comparison with previous studies examining hemodynamic
ﬂuctuations associated with carotid interventions.6,8,9,14-17
We further deﬁned CS-HI as prolonged hypertension,
hypotension, and/or bradycardia lasting greater than
1 hour, a subgroup which comprised 63% of all CAS proce-
dures in our series.
Our results demonstrate that it is prolonged HI, and
not merely the presence of periprocedural HI alone, that
is clinically signiﬁcant. Eight percent of patients with
persistent HI in our series suffered from a periprocedural
stroke compared with only 1% in patients without pro-
longed HI (P ¼ .03). In an early report by Dangas and
colleagues,7 prolonged hypotension following CAS was
associated with increased periprocedural morbidity,
including minor strokes (16% vs 3%; P ¼ .03), as well as
higher rates of mortality at 6-month follow-up (20% vs
4.3%; P ¼ .02). A subsequent report examining outcomes
on 500 consecutive CAS procedures found that patients
with prolonged HI were over three times more likely to
develop a major adverse clinical event or stroke.6 More
Table V. Baseline demographics, comorbidities, and
carotid stenosis disease characteristics of patients with and
without CS-HI following CAS
CS-HI,
No. (%) or
mean 6 SD
(n ¼ 116)
All others,
No. (%) or
mean 6 SD
(n ¼ 141) P
Demographics
Age, years 71 6 10 70 6 10 .45
Gender, female 48 (41) 37 (26) .01
Comorbidities
Hypertension 108 (93) 120 (85) .05
Prior stroke 37 (32) 36 (26) .27
Atrial ﬁbrillation 14 (11) 14 (10) .59
Prior MI 14 (12) 28 (20) .13
CRIa 20 (17) 34 (24) .84
COPD 9 (8) 27 (19) .01
Hyperlipidemia 73 (63) 91 (65) .80
Tobacco use 62 (53) 82 (58) .45
CAD 61 (53) 83 (59) .32
Diabetes 31 (27) 54 (38) .06
Previous ipsilateral carotid
intervention
CEA 36 (31) 30 (21) .09
CAS 1 (1) 9 (6) .03
Symptoms
None 83 (72) 103 (73) .89
TIA 24 (21) 35 (25) .46
Stroke 9 (8) 3 (2) .04
Stenosis, % (mean 6 SD) 86 6 8 86 6 7 >.99
Contralateral carotid
occlusion
15 (13) 13 (9) .55
Stenosis, % .57
60-69 3 (3) 1 (1)
70-79 6 (5) 10 (7)
80-89 47 (41) 60 (43)
>90 60 (52) 70 (50)
Laterality .12
Left 64 (55) 64 (45)
Right 52 (45) 77 (55)
CAD, Coronary artery disease; CAS, carotid angioplasty and stenting; CEA,
carotid endarterectomy; COPD, chronic obstructive pulmonary disease;
CRI, chronic renal insufﬁciency; CS-HI, clinically signiﬁcant hemodynamic
instability;MI, myocardial infarction; SD, standard deviation; TIA, transient
ischemic attack.
aCreatinine $1.5 mg/dL.
Table VI. Independent predictors for CS-HI,
multivariate analysis
Variable OR 95% CI P
COPD 0.34 0.15-0.80 .01
Recent stroke 5.24 1.28-21.51 .02
CI, Conﬁdence interval; COPD, chronic obstructive pulmonary disease;
CS-HI, clinically signiﬁcant hemodynamic instability; OR, odds ratio.
Table VII. Periprocedural complications
CS-HI, No. (%)
or mean 6 SD
(n ¼ 116)
All others,
No. (%) or
mean 6 SD
(n ¼ 141) P
Mortality 1 (1) 0 (0) .45
Stroke 9 (8) 2 (1) .03
MI 1 (1) 0 (0) .45
Respiratory failure 0 (0) 0 (0) >.99
Access site complications 7 (6) 4 (3) .23
Renal failure 0 (0) 1 (0) >.99
Length of stay, days
Intensive care unit 0.22 6 1.00 0.07 6 0.38 .13
Total 2.30 6 2.03 1.93 6 1.76 .13
CS-HI, Clinically signiﬁcant hemodynamic instability; MI, myocardial
infarction.
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their series of 416 patients undergoing elective CAS
procedures. Similar to our ﬁnding, 9% of patients with
prolonged HI experienced neurologic complications in
their study compared with only 2% in those patients
without prolonged HI (P ¼ .02). The same report found
that patients with prolonged HI were noted to have
higher rates of 30-day mortality (4% vs 1%; P ¼ .05),
cardiopulmonary comorbidity (20% vs 2%; P ¼ .03), renal
insufﬁciency (7% vs 1%; P ¼ .05), pseudoaneurysm at
access site (4% vs 1%; P ¼ .05), and hemorrhagic compli-
cations (13% vs 1%; P ¼ .01).4
The question as to whether HI, particularly CS-HI,
represents a cause of periprocedural stroke or is simply
a manifestation of the neurovascular pathophysiology
resulting from or leading up to stroke is difﬁcult toascertain. Based on our experience and available data, we
believe the pathogenesis of periprocedural stroke in this
setting is multifactorial. Indeed, HI is likely causative at
times and a result in others.
Cerebral embolization of carotid plaque occurs during
all CAS procedures. With increasing experience and
advances in endovascular technology d especially the
advent of embolic protection devicesd the relative embolic
insult to the brain has decreased since the early introduction
of endovascular carotid interventions.18 Nevertheless,
varying degrees of cerebral embolization remain. The pres-
ence of prolonged periprocedural HI, particularly hypoten-
sion, may impede clearance of embolic atheromatous debris
in the distal intracranial circulation and predispose to cere-
brovascular insult.19 In addition, the permissive role of
hypertension in the development of acute periprocedural
thromboembolic stroke, as exhibited by nearly half of the
patients in our cohort with periprocedural stroke, is difﬁ-
cult to determine but may relate to increased susceptibility
of carotid plaque to disrupt, fracture, or ulcerate during
periods of arterial hypertension. Furthermore, we also
theorize that there are often silent emboli during carotid
interventions that, while clinically insigniﬁcant, will predis-
pose to vascular insufﬁciency. Such lesions may become
symptomatic when compounded by CAS-associated hemo-
dynamic derangements. These notions reinforce the impor-
tance of early recognition and therapeutic intervention of
periprocedural HI following CAS procedures, particularly
given the poor cardiovascular status and comorbid burden
inherent in this patient population.
Table VIII. Impact of speciﬁc hemodynamic derangements on periprocedural complications
Stroke,
No. (%)
MI,
No. (%)
Mortality,
No. (%)
Renal failure,
No. (%)
Access site,a
No. (%)
Respiratory failure,
No. (%)
Transient HI <1 hourb (n ¼ 100)
Hypertension (n ¼ 56) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0)
Hypotension (n ¼ 41) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0)
Bradycardia (n ¼ 63) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
CS-HI >1 hourb (n ¼ 116)
Hypertension (n ¼ 52) 5 (10) 0 (0) 0 (0) 0 (0) 4 (8) 0 (0)
Hypotension (n ¼ 18) 2 (11) 0 (0) 0 (0) 0 (0) 2 (11) 0 (0)
Bradycardia (n ¼ 82) 3 (4) 0 (0) 1 (1) 0 (0) 4 (5) 0 (0)
CS-HI, Clinically signiﬁcant hemodynamic instability; HI, hemodynamic instability; MI, myocardial infarction.
aIncludes femoral artery pseudoaneurysm, arterial dissection, or groin hematoma requiring operative intervention.
bSome patients developed derangements in multiple hemodynamic parameters (eg, hypotension and bradycardia) such that the total sum of cases involving
hypertension, hypotension, and/or bradycardia exceeds the total number of cases categorized as either transient HI or CS-HI.
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ipsilateral stroke was the only predictor of periprocedural
HI in our analysis, with these patients over ﬁve times
more likely to develop hemodynamic lability following
CAS procedures compared with other patients. This repre-
sents a novel ﬁnding. Previous studies have shown impair-
ment in both parasympathetic and sympathetic cardiovascular
regulatory systems, characterized by compromised auto-
nomic adjustment of heart rate and vascular tone to sudden
blood pressure changes, in patients with history of recent
stroke.20-22 Hilz et al20 assessed National Institutes of
Health Stroke Scale scores and parameters of autonomic
cardiovascular modulation in 50 patients with acute
ischemic stroke and compared data with that of healthy
controls. Their results demonstrated that increasing stroke
severity was associated with progressive loss of overall
cardiovascular autonomic modulation, decline in parasym-
pathetic tone, and baroreﬂex sensitivity, as well as progres-
sive shift toward sympathetic dominance. In addition,
other reports have noted autonomic dysfunction in such
patients to be reﬂected by increased levels of corticosteroids
and plasma catecholamines, as well as baseline heart rate
variability.23-25 The combination of autonomic dysfunction
and irregularities in baseline hemodynamics and endocrine
function may therefore predispose patients with prior stroke
toHI, particularly hypertension, following CAS procedures.
In our series, however, patients with a history of recent (n¼
12) or remote (n ¼ 62) stroke who developed periproce-
dural HI did not show a predilection toward any particular
hemodynamic derangement. While our data alone are insuf-
ﬁcient to generate a recommendation for the optimal timing
of CAS procedures after prior strokes, we generally follow
the same approach as we do for those patients undergoing
carotid endarterectomy. That is, we generally wait
a minimum of 2 to 4 weeks after stroke before intervention
unless a patient has recurrent or crescendo neurologic
symptoms that would otherwise demand earlier treatment.
Other studies have cited various carotid disease and
angiographic characteristics to be associated with develop-
ment of HI, including lesions involving the carotid
bulb,7,13,15 plaque calciﬁcation,6,26 eccentric posteriorcarotid plaque,13 ﬁbrous morphologic features,26 right-sided
carotid disease,13 contralateral carotid stenosis (>60%),15
and length of stenosis.15
Our analysis did not reveal any baseline demographic
predictors of HI. We did, however, ﬁnd that patients
with COPD were at reduced risk of HI after CAS. The
protective role of COPD on HI in this setting may be
related to the complex physiologic basis by which auto-
nomic dysfunction occurs in patients with COPD. The
signiﬁcant intrathoracic pressure changes seen in these
patients may produce ﬂuctuations in cardiac function and
systemic blood pressure resulting in baroreceptor-mediated
compensatory changes in heart rate.27 Patients with COPD
have been shown to have impaired baroreﬂex sensitivity
leading to an increase in sympathetic activity through
inhibitory afferent pathways.28 Moreover, elevated pulmo-
nary arterial pressures and hypoxia, both of which may be
present in those with COPD, have been shown to indepen-
dently alter baroreﬂex sensitivity.29 The presence of such
baroreﬂex insensitivity may attenuate the carotid barore-
ceptor stimulation elicited during CAS procedures and
decrease the potential to develop periprocedural HI.
Gupta et al6 posited a similar mechanism to explain the
protective effect of diabetes and tobacco use on HI
observed in their series following CAS. They suggested
that long-term smoking impairs the carotid baroreceptor
response and augments sympathetic tone, thereby
increasing arterial blood pressure and heart rate.6,30 The
attenuated parasympathetic function seen in diabetes is
similarly associated with a co-existing autonomic impair-
ment of the cardiovascular system.31,32 Interestingly, our
data did show a trend toward a protective effect of diabetes
on CS-HI in univariate analysis, but this failed to reach
statistical signiﬁcance.
Several previous reports have identiﬁed additional
preoperative variables predisposing to HI after endovascu-
lar carotid intervention, including increased age, coronary
artery disease, low ejection fraction (<25%), and previous
MI.4,6,7,9,33,34 Trocciola et al33 found female sex to be
associated with periprocedural hypotension requiring pro-
longed vasopressor use. Female gender did prove to
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P ¼ .01) in our univariate analysis but was no longer signif-
icant following multivariate analysis. In an early report,
Howell and colleagues35 postulated that patients with
very high SBP may be more sensitive to carotid sinus stim-
ulation and thus may be more susceptible for the develop-
ment of HI. They identiﬁed elevated baseline SBP
(>180 mm Hg) to be an independent predictor for HI
and neurologic events following CAS. In our series, the
majority of patients were noted to have baseline hyperten-
sion, and this may partially explain our high incidence of
HI given that any patient exhibiting an SBP >160 mm
Hg during or after the CAS procedure was classiﬁed as
having HI. Post-hoc analysis did demonstrate that all 11
patients suffering from periprocedural stroke in our series
had a history of baseline hypertension, with ﬁve of these
patients experiencing hypertension following CAS.
Limitations of this study include its retrospective
nature and potential for patient selection and treatment
bias. Established criteria for patient selection were used,
however, and our treatment approach did not deviate
signiﬁcantly from our technical protocol over the study
period. The small number of adverse outcomes limits our
multivariate statistical model and increases the chance of
type II error.
In conclusion, our study reveals that HI is a common
occurrence following CAS procedures. Symptomatic
carotid stenosis characterized by recent ipsilateral stroke
was shown to be an independent risk factor for the devel-
opment of periprocedural HI. Conversely, preoperative
COPD demonstrated a protective effect against HI. While
the presence of periprocedural HI alone did not portend
a worse clinical outcome, prolonged HI was associated
with increased incidence of stroke. Expeditious pharmaco-
logic intervention to control and prevent periprocedural
HI is of critical importance to minimize the risk of adverse
clinical outcomes after CAS. Additional investigations are
warranted to better elucidate the inﬂuence of various clin-
ical and procedural variables on the development of HI, as
well as to develop an aggressive interventional strategy to
promptly treat CAS-associated HI.AUTHOR CONTRIBUTIONS
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